Inventor · disambiguated record
Jorge Alsina-Fernandez
Also filed as: ALSINA-FERNANDEZ JORGE
22 granted patents·20 pending applications·130 citations·filing 2005–2025
94Inventor score
Files withLILLY CO ELI35ALSINA-FERNANDEZ JORGE3ZHANG LIANSHAN2BOKVIST BENGT KRISTER1ELI LILLY AND COMPANY PATENT D1
Top patents by PatentIndex Score
42 records- 0195US9474780B2GIP and GLP-1 co-agonist compoundsLILLY CO ELI·Filed 2016·Granted Oct 25, 2016·75 cites·18 claims
- 0293US11542313B2Incretin analogs and uses thereofLILLY CO ELI·Filed 2018·Granted Jan 3, 2023·7 cites·26 claims
- 0392US11254721B2GIPR-agonist compoundsLILLY CO ELI·Filed 2020·Granted Feb 22, 2022·5 cites·3 claims
- 0491US11897926B2GIPR-agonist compoundsLILLY CO ELI·Filed 2022·Granted Feb 13, 2024·3 cites·4 claims
- 0591US7582608B2Selective VPAC2 receptor peptide agonistsLILLY CO ELI·Filed 2006·Granted Sep 1, 2009·15 cites·3 claims
- 0688US11084861B2GIP/GLP1 co-agonist compoundsLILLY CO ELI·Filed 2019·Granted Aug 10, 2021·6 cites·10 claims
- 0787US9884093B2Glucagon receptor agonistsLILLY CO ELI·Filed 2016·Granted Feb 6, 2018·5 cites·15 claims
- 0885US12371465B2Incretin analogs and uses thereofLILLY CO ELI·Filed 2024·Granted Jul 29, 2025·0 cites·10 claims
- 0983US9764004B2Glucagon receptor agonistsLILLY CO ELI·Filed 2016·Granted Sep 19, 2017·3 cites·12 claims
- 1082US11834486B2Incretin analogs and uses thereofLILLY CO ELI·Filed 2018·Granted Dec 5, 2023·3 cites·22 claims
- 1181US12365716B2Incretin analogs and uses thereofLILLY CO ELI·Filed 2022·Granted Jul 22, 2025·0 cites·14 claims
- 1280US2025313605A1Incretin analogs and uses thereofLILLY CO ELI·Filed 2025·Application pending·0 cites
- 1378US2025051415A1Gip/glp1 co-agonist compoundsLILLY CO ELI·Filed 2024·Application pending·0 cites
- 1477US8367607B2Oxyntomodulin peptide analogueLILLY CO ELI·Filed 2010·Granted Feb 5, 2013·4 cites·18 claims
- 1573US12295987B2Method of using a GIP/GLP1 co-agonist for diabetesLILLY CO ELI·Filed 2019·Granted May 13, 2025·1 cites·2 claims
- 1673US2024218031A1Gipr-agonist compoundsLILLY CO ELI·Filed 2023·Application pending·0 cites
- 1770US12453758B2Method of using a GIP/GLP1 co-agonist for diabetesLILLY CO ELI·Filed 2025·Granted Oct 28, 2025·0 cites·8 claims
- 1870US8415296B2Oxyntomodulin peptide analogueALSINA-FERNANDEZ JORGE·Filed 2010·Granted Apr 9, 2013·3 cites·18 claims
- 1970US2024190936A1Incretin Analogs and Uses ThereofLILLY CO ELI·Filed 2023·Application pending·0 cites
- 2069US12252524B2GIP/GLP1 co-agonist compoundsLILLY CO ELI·Filed 2021·Granted Mar 18, 2025·0 cites·20 claims
- 2164US2024174727A1Long-acting natriuretic peptides and uses thereofLILLY CO ELI·Filed 2023·Application pending·0 cites
- 2264US2025163119A1Compounds for the treatment of diabetes or obesityLILLY CO ELI·Filed 2024·Application pending·0 cites
- 2360US7897573B2Selective VPAC2 receptor peptide agonistsLILLY CO ELI·Filed 2009·Granted Mar 1, 2011·0 cites·6 claims
- 2460US2008146500A1Selective Vpac2 Receptor Peptide AgonistsBOKVIST BENGT KRISTER·Filed 2005·Application pending·0 cites
- 2554US2018104312A1Glucagon receptor agonistsLILLY CO ELI·Filed 2017·Application pending·0 cites
- 2653US9695225B2Peptide compound for treatment of severe hypoglycemiaLILLY CO ELI·Filed 2014·Granted Jul 4, 2017·0 cites·8 claims
- 2753US9688736B2Compound for treatment of severe hypoglycemiaLILLY CO ELI·Filed 2014·Granted Jun 27, 2017·0 cites·8 claims
- 2853US2008318845A1Selective Vpac2 Receptor Peptide AgonistsLILLY CO ELI·Filed 2005·Application pending·0 cites
- 2952US12410227B2Incretin analogs and uses thereofLILLY CO ELI·Filed 2020·Granted Sep 9, 2025·0 cites·33 claims
- 3051US2009118167A1Selective Vpac2 Receptor Peptide AgonistsELI LILLY AND COMPANY PATENT D·Filed 2005·Application pending·0 cites
- 3150US2023265151A1Gip/glp1 co-agonist compoundsLILLY CO ELI·Filed 2021·Application pending·0 cites
- 3249US2008194482A1Selective Apac2 Receptor Peptide AgonistsALSINA-FERNANDEZ JORGE·Filed 2006·Application pending·0 cites
- 3346US2022125885A1Glucagon analog agonists and methods of using the sameLILLY CO ELI·Filed 2020·Application pending·0 cites
- 3446US2009082276A1Selective vpac2 receptor peptide agonistsZHANG LIANSHAN·Filed 2007·Application pending·0 cites
- 3546US2010048460A1Selective vpac2 receptor peptide agonistsZHANG LIANSHAN·Filed 2007·Application pending·0 cites
- 3644US10894817B2Fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney diseaseLILLY CO ELI·Filed 2017·Granted Jan 19, 2021·0 cites·24 claims
- 3744US2016311882A1Novel Compound for Treatment of Severe HypoglycemiaLILLY CO ELI·Filed 2014·Application pending·0 cites
- 3842US2014056893A1Homodimeric ProteinsLILLY CO ELI·Filed 2013·Application pending·0 cites
- 3941US2008026996A1Selective Vpac2 Receptor Reptide AgonistsLILLY CO ELI·Filed 2005·Application pending·0 cites
- 4040US2008085860A1Selective Vpac2 Receptor Peptide AgonistsLILLY CO ELI·Filed 2005·Application pending·0 cites
- 4140US2008096811A1Selective vpac2 receptor peptide agonistsLILLY CO ELI·Filed 2005·Application pending·0 cites
- 4230US8815811B2Peptides and methods for their preparation and useALSINA-FERNANDEZ JORGE·Filed 2011·Granted Aug 26, 2014·0 cites·16 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →